Skip to content
CDC

Antimicrobial Resistance

Cefepime-resistant Enterobacter

% Resistant in 2024

13.0% Resistant

Number of Resistant Isolates of the Total Number of Isolates Tested In 2024

417 Resistant

/ 3,196 Tested

% Resistant by Patient Age in 2024

Pediatric:
12.8% Resistant
Adult:
13.1% Resistant
Data for this phenotype may be impacted by surveillance changes. Caution should be used when interpreting these results.

Pathogen Profile

Cefepime-resistant Enterobacter

Enterobacter spp. cause pneumonia, urinary tract infections, and bloodstream infections in hospitalized patients. These organisms can easily develop resistance to the extended-spectrum cephalosporins such as ceftriaxone, cefotaxime, and ceftazidime; such resistance can even develop (i.e. inducible resistance) in previously susceptible isolates while patients are receiving therapy with one of these drugs. Cefepime can be an important drug to treat infections caused by Enterobacter spp., including those resistant to other extended-spectrum cephalosporins. Resistance to cefepime among some Enterobacter spp. makes infections with such bacteria more difficult to treat.

Current Threat Report

Threat LevelNot Currently Rated

Source: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2024

Years Included
2011 - 2024
Resources

Geographic Locations

Antimicrobial resistance varies by location, driven by a number of factors, including antibiotic use and infection control practices in individual healthcare facilities, the underlying health and age of the patient population, and regional spread from nearby locations.

Percent Cefepime resistance Among Enterobacter spp. by State Map

This map shows the variation in % cefepime resistance among Enterobacter spp. causing all event types in 2024.

Percent Cefepime resistance Among Enterobacter spp. by State

Percent Cefepime resistance Among by State
Locationvalue
Alabama12.8
AlaskaInsufficient Data
Arizona7.3
Arkansas17.4
California11.8
Colorado23.2
ConnecticutInsufficient Data
DelawareInsufficient Data
District of Columbia14.3
Florida12.9
Georgia14.5
HawaiiInsufficient Data
IdahoInsufficient Data
Illinois21.3
Indiana12.9
IowaInsufficient Data
KansasInsufficient Data
Kentucky12.1
Louisiana4.7
MaineInsufficient Data
Maryland19.5
Massachusetts13
Michigan12.6
Minnesota10.5
Mississippi11.5
Missouri8.6
MontanaInsufficient Data
Nebraska16
NevadaInsufficient Data
New HampshireInsufficient Data
New Jersey10.3
New MexicoInsufficient Data
New York13.3
North Carolina17.2
North DakotaInsufficient Data
Ohio4.9
Oklahoma8.7
Oregon29.6
Pennsylvania12.5
Puerto Rico50
Rhode IslandInsufficient Data
South Carolina14.5
South DakotaInsufficient Data
Tennessee14.1
Texas11.8
Utah20
VermontInsufficient Data
Virginia4.7
Washington13.8
West Virginia4.3
Wisconsin11.6
WyomingInsufficient Data

Percent Cefepime resistance Among Enterobacter spp. by State List

Geography

Geography
statevalue
United States13.0%
Alabama12.8%
AlaskaNo Data
Arizona7.3%
Arkansas17.4%
California11.8%
Colorado23.2%
ConnecticutNo Data
DelawareNo Data
District of Columbia14.3%

Changes Over Time in Cefepime resistance Among Enterobacter spp.

This graph displays percent antimicrobial resistance from 2011 to 2024 for all event types. Blank areas of the chart represent 0% resistance, indicating that zero resistant pathogens were reported for the selected year, phenotype, and HAI type. “Insufficient data” indicates that less than 20 pathogens were isolated and tested for resistance.

Due to definition changes, caution should be used when reviewing this phenotype over time.

Changes Over Time in Cefepime resistance Among Enterobacter spp.
Year% Resistant
20116.8
20127.5
20138.1
20148.4
20154.1
20164.1
20172.8
20189.7
20199.5
202013
202111.4
202213.4
202314.6
202413

Healthcare Facility Type

The setting or type of healthcare facility can influence the types of procedures and prevention measures that are related to healthcare-associated infections and antimicrobial resistance.

Cefepime resistance Among Enterobacter spp. by Hospital Type

This graph displays percent antimicrobial resistance by hospital type in 2024.

Percent resistant Among Enterobacter spp. by Hospital Type

Percent resistant Among Enterobacter spp. by Hospital Type
Hospital Type% Resistant
General Acute Care Hospitals12.8
Long Term Acute Care Hospitals23.9
Inpatient Rehabilitation Facilities11.3

Footnotes

  • HAIs include Catheter-associated Urinary Tract Infections (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), and Surgical Site Infections (SSI).
  • CI (Confidence Interval) - The national, regional, and state-level data included in Antimicrobial Resistance information are displayed with 95% confidence intervals around the percent resistance, which were calculated using a mid-P exact test and are an indication of precision.
  • Map legends are classified using the Jenks Natural Breaks method.
  • Klebsiella aerogenes is only counted in this phenotype for 2020 events and forward. Prior to 2020, this pathogen was referred to as Enterobacter aerogenes.
  • The definition for this phenotype underwent changes in 2021. For more information, refer to the AR&PSP Phenotype Definitions.